Abstract:Over the past 14 years, Health Information Technology (Health IT) regulation has been successful in transitioning health care providers in the United States from paper-based to electronic health records. This success was largely a result of the Health Information Technology for Economic and Clinical Health Act,[1] which offered incentive payments for Medicare and Medicaid providers who made Meaningful Use of Certified Health IT. During this period, the Office of the National Coordinator (ONC) has periodically updated the certification criteria to include various capabilities, including computerized provider order entry, electronic prescribing, transitions of care, clinical decision support, and patient education. However, even the best considered policies can lead to challenges in implementation. Here we cite an example of a successful public/private partnership to identify and reconcile one such challenge. A significant update to the certification criteria occurred in 2020, when ONC added a new Application Programming Interface criterion that required support for Fast Healthcare Interoperability Resources R4.[2] However, in the same 2020 update, ONC also required that certified Health IT support the Consolidated-Clinical Document Architecture (C-CDA) for transitions of care, clinical information reconciliation, care plans, and transmission of data to third parties and public health agencies. ONC gave Health IT developers until December 31, 2022, to be in compliance with the C-CDA requirements. Although ONC required adoption of the latest version of C-CDA, many of the templates in the latest version were originally developed a decade ago. In particular, the Substance or Device Allergy—Intolerance Observation (v2) was included in the Health Level Seven International (HL7) Draft Standard for Trial Use ballot in September 2013.[3] Buried on page 603 of 930 in that document, Table 491 required that to represent a code for an allergy to a substance, the C-CDA "SHALL" contain a code from the value set 2.16.840.1.113762.1.4.1010.1 ( Substance-Reactant for Intolerance ). This grouping value set included a specific value set to represent drug classes called Medication drug class for allergen intolerance with Object Identifier 2.16.840.1.113762.1.4.1114.14. This value set contained SNOMED CT codes for drug classes as required by United States Core Data for Interoperability (USCDI) v1.[4] Fast forwarding to 2022, Health IT developers were using an ONC testing tool[5] to test their compliance with the C-CDA requirement. For the concept of an allergy code noted above, the testing tool validated that the code was contained in the required value set. Unfortunately, several common drug classes were missing from the required value set. Using Medi-Span as a data source (Wolters Kluwer Health, Indianapolis, IN), we found 48 SNOMED CT codes that were missing from this value set, including common drug class concepts such as low-molecular weight heparin (87233003), β-2 adrenergic receptor agonists (320073005), selective serotonin reuptake inhibitors (349854005), and loop diuretics (830118008). As a result of the omission of these concepts from the value set, it became difficult for Health IT developers to comply fully with the ONC regulation, since there was no way to represent many actual patient allergies to medication classes using the required value set. The C-CDA documents that these developers were submitting to the ONC testing tool were failing the validation test. If instead of the verb "SHALL," the C-CDA template for allergies had used the verb "SHOULD" in the HL7 ballot 10 years ago, then compliance would have been possible by including codes that were outside of the value set, but admittedly with reduced consistency for the additional concepts. For step 1, we worked with HL7 in the Fall of 2022 to update the value set. For step 2, we worked with ONC in January and February of 2023 to update the testing tool to use the new version of the value set. We would note that both HL7 and ONC were helpful and cooperative with the necessary updates. We believe this report can serve as a model for ongoing collaboration between regulatory bodies and the implementation community to address any implementation challenges that will inevitably arise. While draft regulations are already subject to a public comment period prior to being finalized, it may be difficult for implementers to understand the full implications of these regulations until they are tested with real world data. Therefore, a process for addressing implementation challenges postregulation also needs to be in place. This process for postregulation surveillance could be modeled after the process used for postmarketing surveillance in the pharmaceutical industry. Reports of implementation challenges could be submitted to ONC for review, which in some cases may lead to -Abstract Truncated-

CTSA Institution Responses to Proposed Common Rule Changes: Did They Get What They Wanted?

Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act

Major Rule Changes Proposed for Human-Subject Studies

Review of the Latest Revision of Common Rule in the United States

FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform

New and Improved? 21st Century Cures Act Revisions to Certificates of Confidentiality

Instruction in the Responsible Conduct of Research: An Inventory of Programs and Materials within CTSAs

Experiences and challenges with the new European Clinical Trials Regulation

Health IT Regulation: Report of an Implementation Challenge

Potential Implications of Recent and Proposed Changes in the Regulatory Oversight of Solid Organ Transplantation in the United States

Evaluating the discoverability of supporting research materials in ClinicalTrials.gov for US federally funded COVID-19 clinical studies

Integrating dissemination and implementation sciences within Clinical and Translational Science Award programs to advance translational research: Recommendations to national and local leaders

Public perspectives on increased data sharing in health research in the context of the 2023 National Institutes of Health Data Sharing Policy

Rescuing Informed Consent: How the new "Key Information" and "Reasonable Person" Provisions in the Revised U.S. Common Rule open the door to long Overdue Informed Consent Disclosure Improvements and why we need to walk Through that door

Streamlining the Conduct of Cancer Clinical Trials: New Standard Data Collection Practices for National Cancer Institute Late Phase Clinical Studies

Abstract B058: Preliminary findings of a multilevel community-based clinical trials and genomic navigation program implemented in the southern United States

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.

Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Consent Form Reporting on ClinicalTrials.Gov, 2013-2023

Ethical acceptability of human challenge trials: Consultation with the US public and with research personnel